0000000000881804

AUTHOR

N. Fadeeva

showing 3 related works from this author

Silicon detectors for the sLHC

2011

In current particle physics experiments, silicon strip detectors are widely used as part of the inner tracking layers. A foreseeable large-scale application for such detectors consists of the luminosity upgrade of the Large Hadron Collider (LHC), the super-LHC or sLHC, where silicon detectors with extreme radiation hardness are required. The mission statement of the CERN RD50 Collaboration is the development of radiation-hard semiconductor devices for very high luminosity colliders. As a consequence, the aim of the RandD programme presented in this article is to develop silicon particle detectors able to operate at sLHC conditions. Research has progressed in different areas, such as defect …

Nuclear and High Energy PhysicsSiliconPhysics::Instrumentation and DetectorsLHC; High luminosity collider; radiation damageCharge collection efficiencychemistry.chemical_elementHigh luminosity colliderTracking (particle physics)Nuclear physicsRadiation damageSilicon particle detectors; Radiation damage; Irradiation; Charge collection efficiencyInstrumentationRadiation hardeningPhysicsLuminosity (scattering theory)Large Hadron ColliderDetectorSemiconductor deviceEngineering physicsSilicon particle detectorschemistryHigh Energy Physics::ExperimentIrradiationLHCParticle physics experiments
researchProduct

220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabin…

2016

Oncologymedicine.medical_specialtybiologybusiness.industryCancerHematologyGastroesophageal Junctionmedicine.diseaseOxaliplatinCapecitabine03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinebiology.proteinmedicine030212 general & internal medicineAntibodyClaudinbusinessIMAB362Epirubicinmedicine.drugAnnals of Oncology
researchProduct

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or…

2016

Background: IMAB362, a chimeric monoclonal antibody that mediates specific killing of cancer cells expressing the tight junction protein Claudin18.2 (CLDN18.2) by activation of immune effector mechanisms, has demonstrated single-agent activity and tolerability in patients ( pts) with heavily pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by immunohistochemistry (CLAUDETECT® 18.2 Histology Kit). Eligible pts had a CLDN18.2 expression of ≥2+ in ≥40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2…

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseLoading doseOxaliplatinCapecitabine03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTolerabilityTrastuzumab030220 oncology & carcinogenesisInternal medicineMedicineAdenocarcinomabusinessEpirubicinmedicine.drugAnnals of Oncology
researchProduct